Investors with a lot of money to spend have taken a bearish stance on ImmunityBio IBRX.
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with IBRX, it often means somebody knows something is about to happen.
So how do we know what these investors just did?
Today, Benzinga's options scanner spotted 19 uncommon options trades for ImmunityBio.
This isn't normal.
The overall sentiment of these big-money traders is split between 31% bullish and 63%, bearish.
Out of all of the special options we uncovered, 5 are puts, for a total amount of $193,809, and 14 are calls, for a total amount of $1,151,587.
Expected Price Movements
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $1.5 to $15.0 for ImmunityBio during the past quarter.
Analyzing Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in ImmunityBio's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to ImmunityBio's substantial trades, within a strike price spectrum from $1.5 to $15.0 over the preceding 30 days.
ImmunityBio Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| IBRX | CALL | SWEEP | BEARISH | 01/17/25 | $6.6 | $6.0 | $6.0 | $2.50 | $306.6K | 3.1K | 618 |
| IBRX | CALL | SWEEP | BULLISH | 01/17/25 | $6.0 | $5.5 | $5.5 | $3.00 | $194.7K | 557 | 389 |
| IBRX | CALL | SWEEP | BEARISH | 01/17/25 | $5.9 | $5.7 | $5.7 | $2.50 | $114.0K | 3.1K | 818 |
| IBRX | CALL | SWEEP | BULLISH | 05/17/24 | $4.1 | $3.9 | $4.1 | $5.00 | $91.4K | 2.9K | 3 |
| IBRX | CALL | TRADE | BULLISH | 01/17/25 | $7.3 | $5.7 | $7.1 | $1.50 | $88.7K | 166 | 0 |
About ImmunityBio
ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. Geographically, the company operates in United States and Europe. Majority of the revenue is generated from Europe.
Having examined the options trading patterns of ImmunityBio, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Present Market Standing of ImmunityBio
- Currently trading with a volume of 10,119,031, the IBRX's price is down by -6.84%, now at $8.38.
- RSI readings suggest the stock is currently may be approaching overbought.
- Anticipated earnings release is in 13 days.
What Analysts Are Saying About ImmunityBio
1 market experts have recently issued ratings for this stock, with a consensus target price of $6.0.
- Maintaining their stance, an analyst from Piper Sandler continues to hold a Neutral rating for ImmunityBio, targeting a price of $6.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ImmunityBio with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
